To meet the urgent need to expand laboratory capacity, the Centers for Medicare & Medicaid Services yesterday announced a relaxed enforcement policy under the Clinical Laboratory Improvement Amendments during the COVID-19 public health emergency with respect to review of pathology slides, proficiency testing, alternate collection devices, and requirements for a CLIA certificate. Among other flexibilities, CMS said the policy will enable:

  • Pathologists to review pathology slides remotely if certain defined conditions are met;

  • U.S. laboratories performing COVID-19 testing that apply for CLIA certification to begin testing as quickly as possible; and

  • Laboratories within a hospital/university hospital campus to hold a single CLIA certificate for the laboratory sites within the same physical location or street address

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…